A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503)

BACKGROUND: The Notch signalling pathway has been implicated in tumour initiation, progression, angiogenesis and development of resistance to vascular endothelial growth factor (VEGF) targeting, providing a rationale for the combination of RO4929097, a γ-secretase inhibitor, and cediranib, a VEGF re...

Descripción completa

Detalles Bibliográficos
Autores principales: Sahebjam, S, Bedard, P L, Castonguay, V, Chen, Z, Reedijk, M, Liu, G, Cohen, B, Zhang, W-J, Clarke, B, Zhang, T, Kamel-Reid, S, Chen, H, Ivy, S P, Razak, A R A, Oza, A M, Chen, E X, Hirte, H W, McGarrity, A, Wang, L, Siu, L L, Hotte, S J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3749563/
https://www.ncbi.nlm.nih.gov/pubmed/23868004
http://dx.doi.org/10.1038/bjc.2013.380

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3749563/
https://www.ncbi.nlm.nih.gov/pubmed/23868004
http://dx.doi.org/10.1038/bjc.2013.380

Ejemplares similares